Epidermal Growth Factor

• & USAGE DIRECTIONS: TAKE 15 MINUTES BEFORE MEALS

DIRECTIONS Take 15 minutes before meals. Adults and children 12 years and older 20 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children between 12 years and 6 years of age 10 drops twice a day in a little water. Hold in the mouth for about 30 seconds then swallow. Children under 6 years 5 drops twice a day in a glass of water.

Stop use and ask doctor if symptoms worsen or persist more than 5 days

1. 1Anaemia240%
2. 2Asthma240%
3. 3Benign Prostatic Hyperplasia120%
4. 4Candida Infection120%
5. 5Chronic Gastritis120%
6. 6Gallbladder Polyp120%
7. 7Hepatic Failure120%
8. 8Myelosuppression120%
9. 9Nasal Septum Deviation120%
10. 10Off Label Use120%
11. 11Oral Candidiasis120%
12. 12Oral Infection120%
13. 13Pneumonia120%
14. 14Rhinitis Allergic120%
15. 15Sinusitis120%

Recent PubMed references pinned to Epidermal Growth Factor as a MeSH major topic. Citations link to pubmed.ncbi.nlm.nih.gov.

• Multi-omics profiling reveals epidermal growth factor as a potential biomarker and therapeutic target in lupus nephritis and ANCA-associated vasculitis with rapidly progressive glomerulonephritis.
  PloS one · 2026 · Xu M, Cheng Q, Xie Y, et al.
  PMID 42213678DOI 10.1371/journal.pone.0349307
• Efficacy and safety of recombinant human epidermal growth factor combined with fractional carbon dioxide laser for facial atrophic acne scars: a systematic review and meta-analysis of randomized trials.
  Lasers in medical science · 2026 · Zhou S, Guo C, Zhai J, et al.
  PMID 42168448DOI 10.1007/s10103-026-04881-w
• A Randomized, Double-Blinded Pilot Study Comparing Synthetic Versus Human-Derived Topical Epidermal Growth Factor for Facial Rejuvenation and Psychosocial Perception.
  Journal of cosmetic dermatology · 2026 · Abud B, McGinn L, Cawthon E, et al.
  PMID 42152512DOI 10.1111/jocd.70927
• Intra-Individual Variability of Urinary EGF and Clusterin, and Effect of Frozen Storage on Stability: Results from UVALID.
  International journal of molecular sciences · 2026 · Moedt E, Vos R, Ju W, et al.
  PMID 42123423DOI 10.3390/ijms27093838
• Sensitive Detection of Epidermal Growth Factor in Lung Cancer Patients by Electrochemical Biosensors.
  Analytical chemistry · 2026 · Valério TL, Hryniewicz BM, Basei FL, et al.
  PMID 42030491DOI 10.1021/acs.analchem.6c01773
• POGLUT2 and POGLUT3: Two essential protein O-glucosyltransferases modifying EGF repeats in extracellular matrix proteins.
  Biochimica et biophysica acta. General subjects · 2026 · Kegley NR, Holdener BC, Haltiwanger RS, et al.
  PMID 41955902DOI 10.1016/j.bbagen.2026.130942
• Dietary targeting of CNBP to rein in the EREG-EGFR cascade and restore homeostasis in colitis-associated colorectal cancer.
  International journal of biological sciences · 2026 · Zhang T, Zhou L, Wang B, et al.
  PMID 41943842DOI 10.7150/ijbs.128354
• Dose-Dependent Inhibition of Protein Glycosylation Reveals Crosstalk between Glycosylation and Phosphorylation in EGF Signaling Pathways.
  Analytical chemistry · 2026 · Liu H, Lin DC, Hu Y, et al.
  PMID 41843583DOI 10.1021/acs.analchem.5c08113

The 10 most recently updated of 1,201 ClinicalTrials.gov registrations naming Epidermal Growth Factor as an intervention. Registration is not evidence of efficacy or safety — reference crosswalk only.

• Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
  Terminated · Phase 2 · Interventional · 648 enrolled · Spectrum Pharmaceuticals, Inc
  NCT03318939updated 2026-06-12
• PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
  Recruiting · Phase 2 · Interventional · 297 enrolled · Kristina A. Fanucci
  NCT07222215updated 2026-06-12
• A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations
  Active not recruiting · Phase 2 · Interventional · 60 enrolled · AstraZeneca
  NCT05801029updated 2026-06-12
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
  Recruiting · Phase 3 · Interventional · 3,680 enrolled · National Cancer Institute (NCI)
  NCT06058377updated 2026-06-12
• A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
  Recruiting · Phase 3 · Interventional · 2,400 enrolled · Merck Sharp & Dohme LLC
  NCT06966700updated 2026-06-12
• PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan
  Recruiting · Observational · 800 enrolled · AstraZeneca
  NCT05573893updated 2026-06-12
• An EAP Treatment Protocol of Zipalertinib
  Available · Expanded access · Taiho Oncology, Inc.
  NCT07601399updated 2026-06-11
• Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer
  Active not recruiting · Phase 1 · Interventional · 36 enrolled · National Cancer Institute (NCI)
  NCT02503722updated 2026-06-11
• Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Solid Tumors and Breast Cancer
  Recruiting · Phase 1 · Interventional · 36 enrolled · National Cancer Institute (NCI)
  NCT07137416updated 2026-06-11
• PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
  Recruiting · Phase 2 · Interventional · 25 enrolled · Glenn J. Hanna
  NCT06239220updated 2026-06-11

Frequently asked questions

What is Epidermal Growth Factor used for?

According to FDA labeling, Epidermal Growth Factor carries indications including: & USAGE DIRECTIONS: TAKE 15 MINUTES BEFORE MEALS. This is a reference summary of labeled uses, not medical advice or a treatment recommendation.